Mineralys Therapeutics (NASDAQ:MLYS) Sets New 52-Week Low – What’s Next?

Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report)’s share price reached a new 52-week low on Friday. The stock traded as low as $14.85 and last traded at $14.8930, with a volume of 253,117 shares. The stock had previously closed at $15.50.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $56.00 target price on shares of Mineralys Therapeutics in a report on Monday, October 12th. UBS Group began coverage on Mineralys Therapeutics in a report on Sunday, October 11th. They set a “neutral” rating and a $29.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Thursday, October 15th. Zacks Research raised Mineralys Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, September 11th. Finally, Wall Street Zen downgraded Mineralys Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Mineralys Therapeutics currently has a consensus rating of “Hold” and an average price target of $43.60.

Read Our Latest Stock Analysis on MLYS

Mineralys Therapeutics Stock Down 1.1%

The firm has a market cap of $1.36 billion, a P/E ratio of -3.52 and a beta of 0.83. The company has a debt-to-equity ratio of 0.15, a quick ratio of 11.83 and a current ratio of 11.83. The firm’s fifty day moving average is $22.66 and its 200 day moving average is $26.18.

Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.09). As a group, equities research analysts anticipate that Mineralys Therapeutics, Inc. will post -4.64 earnings per share for the current fiscal year.

Insider Transactions at Mineralys Therapeutics

In other news, Director Brian Slingsby sold 104,320 shares of the stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $28.81, for a total transaction of $3,005,459.20. Following the transaction, the director owned 7,805,718 shares in the company, valued at approximately $224,882,735.58. This trade represents a 1.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Eric Warren sold 7,438 shares of Mineralys Therapeutics stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $28.12, for a total value of $209,156.56. Following the sale, the insider directly owned 38,400 shares of the company’s stock, valued at approximately $1,079,808. The trade was a 16.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 197,195 shares of company stock worth $5,403,069 over the last three months. Company insiders own 18.94% of the company’s stock.

Hedge Funds Weigh In On Mineralys Therapeutics

Hedge funds have recently bought and sold shares of the business. Jump Financial LLC bought a new position in shares of Mineralys Therapeutics during the third quarter worth approximately $1,961,000. Marshall Wace LLP boosted its stake in shares of Mineralys Therapeutics by 43.3% in the third quarter. Marshall Wace LLP now owns 25,800 shares of the company’s stock valued at $648,000 after buying an additional 7,800 shares during the period. ACT Capital Partners L.P. bought a new stake in shares of Mineralys Therapeutics in the third quarter valued at approximately $2,196,000. Aberdeen Group plc boosted its stake in shares of Mineralys Therapeutics by 29.8% in the third quarter. Aberdeen Group plc now owns 894,403 shares of the company’s stock valued at $22,476,000 after buying an additional 205,168 shares during the period. Finally, Ethic Inc. acquired a new stake in Mineralys Therapeutics during the third quarter worth approximately $269,000. 84.46% of the stock is owned by institutional investors.

About Mineralys Therapeutics

(Get Free Report)

Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing treatments for hypertension and other cardiovascular and kidney conditions associated with excess aldosterone. The company is based in Radnor, Pennsylvania, and was founded in 2019. Its lead product candidate, lorundrostat, is an investigational oral inhibitor of aldosterone synthase. Mineralys is studying the drug as a potential treatment for difficult-to-control hypertension and conditions related to excess aldosterone; it is not an approved or marketed therapy.

Featured Articles

Receive News & Ratings for Mineralys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mineralys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.